Trial Profile
Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD19/CD20 CAR T cell therapy Shanghai Longyao Biotechnology (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Shanghai Longyao Biotechnology
- 05 Jul 2017 New trial record